$2.39T
Total marketcap
$72.34B
Total volume
BTC 50.49%     ETH 15.00%
Dominance

Xtacy Therapeutics Corp. TT5.F Stock

0.02 EUR {{ price }} 23.076925% {{change_pct}}%
COUNTRY
Germany
Exchange
Frankfurt
Market Cap
1.34M EUR
LOW - HIGH [24H]
0.02 - 0.02 EUR
VOLUME [24H]
1.3K EUR
{{ volume }}
P/E Ratio
0
Earnings per share
-0.01 EUR

Xtacy Therapeutics Corp. Price Chart

Xtacy Therapeutics Corp. TT5.F Financial and Trading Overview

Xtacy Therapeutics Corp. stock price 0.02 EUR
Previous Close 8.1 EUR
Open 8.05 EUR
Bid 8 EUR x N/A
Ask 8.2 EUR x N/A
Day's Range 8.05 - 8.05 EUR
52 Week Range 4.04 - 8.2 EUR
Volume 150 EUR
Avg. Volume 2 EUR
Market Cap 75.21M EUR
Beta (5Y Monthly) 0.939436
PE Ratio (TTM) N/A
EPS (TTM) -0.01 EUR
Forward Dividend & Yield N/A (N/A)
Ex-Dividend Date February 11, 2020
1y Target Est N/A

TT5.F Valuation Measures

Enterprise Value 153.42M EUR
Trailing P/E N/A
Forward P/E N/A
PEG Ratio (5 yr expected) N/A
Price/Sales (ttm) 0.16636044
Price/Book (mrq) 1.0183429
Enterprise Value/Revenue 0.339
Enterprise Value/EBITDA -256.253

Trading Information

Xtacy Therapeutics Corp. Stock Price History

Beta (5Y Monthly) 0.939436
52-Week Change 54.71%
S&P500 52-Week Change 20.43%
52 Week High 8.2 EUR
52 Week Low 4.04 EUR
50-Day Moving Average 7.22 EUR
200-Day Moving Average 5.17 EUR

TT5.F Share Statistics

Avg. Volume (3 month) 2 EUR
Avg. Daily Volume (10-Days) 0 EUR
Shares Outstanding 9.27M
Float 5.34M
Short Ratio N/A
% Held by Insiders 29.81%
% Held by Institutions 46.39%
Shares Short N/A
Short % of Float N/A
Short % of Shares Outstanding N/A

Dividends & Splits

Trailing Annual Dividend Rate 0
Trailing Annual Dividend Yield 0%
5 Year Average Dividend Yield N/A
Payout Ratio 0
Last Split Factor

Financial Highlights

Fiscal Year

Fiscal Year Ends March 26, 2023
Most Recent Quarter (mrq) March 26, 2023
Next Fiscal Year End March 26, 2024

Profitability

Profit Margin -0.96%
Operating Margin (ttm) -0.46%
Gross Margin 20.14%
EBITDA Margin -0.13%

Management Effectiveness

Return on Assets (ttm) -0.60%
Return on Equity (ttm) -5.83%

Income Statement

Revenue (ttm) 452.06M EUR
Revenue Per Share (ttm) 49.35 EUR
Quarterly Revenue Growth (yoy) 2.60%
Gross Profit (ttm) 91.08M EUR
EBITDA -598700 EUR
Net Income Avi to Common (ttm) -4347000 EUR
Diluted EPS (ttm) -0.44
Quarterly Earnings Growth (yoy) N/A

Balance Sheet

Total Cash (mrq) 777.2K EUR
Total Cash Per Share (mrq) 0.08 EUR
Total Debt (mrq) 78.35M EUR
Total Debt/Equity (mrq) 107.16 EUR
Current Ratio (mrq) 1.976
Book Value Per Share (mrq) 7.905

Cash Flow Statement

Operating Cash Flow (ttm) -11959000 EUR
Levered Free Cash Flow (ttm) -31164050 EUR

Profile of Xtacy Therapeutics Corp.

Country Germany
State MD
City Hunt Valley
Address 11126 McCormick Road
ZIP 21031
Phone 410 229 1000
Website https://www.tessco.com
Industry Communication Equipment
Sector(s) Technology
Full Time Employees 557

TESSCO Technologies Incorporated engages in manufacture and distribution of technology products and solutions for wireless infrastructure market in the United States and internationally. It operates in two segments, Carrier and Commercial. The company offers base station infrastructure products, including base station antennas, cable and transmission lines, small towers, lightning protection devices, connectors, power systems, enclosures, grounding products, jumpers, miscellaneous hardware products, and mobile antennas to build, repair, and upgrade wireless broadband systems. It also provides network systems products, such as fixed and mobile broadband radio equipment, wireless networking filtering and distributed antenna systems, two-way radios, and security and surveillance products. In addition, the company offers installation, test, and maintenance products comprising analysis equipment; and various frequency, voltage, and power-measuring devices, as well as tools, hardware, GPS and safety products, and replacement and component parts and supplies to install, tune, and maintain wireless communications equipment. The company sells its products to carrier and public network operators, tower owners, program managers, contractors and integrators, private system operators, federal governments, state and local governments, manufacturers, national solutions providers, and value-added resellers under the Ventev brand. TESSCO Technologies Incorporated was founded in 1982 and is headquartered in Hunt Valley, Maryland.

Q&A For Xtacy Therapeutics Corp. Stock

What is a current TT5.F stock price?

Xtacy Therapeutics Corp. TT5.F stock price today per share is 0.02 EUR.

How to purchase Xtacy Therapeutics Corp. stock?

You can buy TT5.F shares on the Frankfurt exchange. Contact your financial advisor to select a broker.

What is the ticker symbol for Xtacy Therapeutics Corp.?

The stock symbol or ticker of Xtacy Therapeutics Corp. is TT5.F.

Which industry does the Xtacy Therapeutics Corp. company belong to?

The Xtacy Therapeutics Corp. industry is Communication Equipment.

How many shares does Xtacy Therapeutics Corp. have in circulation?

The max supply of Xtacy Therapeutics Corp. shares is 83.8M.

What is Xtacy Therapeutics Corp. Price to Earnings Ratio (PE Ratio)?

Xtacy Therapeutics Corp. PE Ratio is now.

What was Xtacy Therapeutics Corp. earnings per share over the trailing 12 months (TTM)?

Xtacy Therapeutics Corp. EPS is -0.01 EUR over the trailing 12 months.

Which sector does the Xtacy Therapeutics Corp. company belong to?

The Xtacy Therapeutics Corp. sector is Technology.